CRPC special-- causes of Enzalutamide resistance, Treatment comparisons in nMCRPC, and Improved OS with Masitinib and Docetaxel

[NPfisherman]

Howdy FPC folks,

So today I thought I would post 3 articles on CRPC-the first deals with Enzalutamide resistance. An evaluation of CTC's and mutations involving Emzalutamide resistance. Knowing your tumor mutations may help you in making treatment decisions regarding Xtandi:

practiceupdate.com/content/...

An interesting note from the study is that: We demonstrate an increased number of BRCA2 alterations post-enzalutamide highlighting importance of serial tumor sampling in CRPC.

POST TREATMENT FAILURE TESTING IS IMPORTANT FOR EVOLUTION OF SOMATIC MUTATIONS !!!!!!!

Next, a comparison of treatments for nMCRPC and the results were rather interesting in regards to how treatments ranked as single agents.

practiceupdate.com/content/...

Lastly, the addition of Masitinib with Docetaxel and Prednisone for MCRPC showed improved overall survival (OS) so for those looking at chemotherapy, this may be something to consider. ( A Combo?? Are you kidding me??? )

onclive.com/view/masitinib-...

Keep them peepers on the Science.....

Don Pescado

[cujoe]

Thanks for continuing to report on the emerging science news, Señor Pescado.

[NPfisherman in reply to cujoe]

You're welcome... The science evolves..... I report.... I found the increased BRCA2 mutation of interest post enzalutamide failure and didn't know that and wonder how many readers had a somatic test post failure, because that could be helpful in determining next therapy-- a PARP inhibitor combo possibly....

Fish

[TheTopBanana]

Thank you!!

[NPfisherman in reply to TheTopBanana]

You're welcome...

Fish

[GreenStreet]

Thanks once again. Really appreciate your knowledge and generosity in sharing.

[NPfisherman in reply to GreenStreet]

Appreciate your appreciation.... There are folks with MCRPC here and it was nice to focus on things that are current that can help them....

Fish